• mTOR pathway antibodies
• Long or difficult peptide synthesis
• Expect “Q” Qualified Antibodies
• Over 180 new antibodies

mTOR Pathway Antibodies

The mTOR pathway regulates many processes such as growth, proliferation, autophagy, ribosome biogenesis and metabolism. We have expanded our selection of mTOR pathway products and announce a comprehensive collection of >100 qualified antibodies targeting mTOR pathway proteins.  Our Epishot™ Antigen Prediction Screen maximizes the epitope specificity of these mTOR pathway antibodies. This expanding collection of mTOR pathway antibodies includes these new protein targets: EIF4B, EIF4E, HGF, VEGF1, VEGF2, VEGF3, STK11, MAPK1, MAPK3, and PI3KCB, PI3KR1, PI3KCG and PI3KR5. See Product Listing

Solutions for Long or Difficult Peptide Custom Synthesis

A core Abgent strength is the synthesis of long or difficult peptides such as branched and cyclic peptides. Cyclic peptides often exhibit improved metabolic stability and increased potency, receptor selectivity, and bioavailability compared to their linear precursors. We have completed numerous cyclic peptide synthesis and peptide epitope mapping projects, providing us a rich set of data demonstrating the specific combinations of amino acids and their positions in the sequence that significantly affect synthetic efficiency. This knowledge, combined with our proprietary chemistry, optimized coupling procedures and coupling temperatures maximizes our success in this area. Get more information on our solutions for long and difficult peptide custom synthesis or obtain a free quote.

Expect “Q” Qualified Antibodies

We are committed to releasing 100% of our new antibodies with supporting validation data such as western blot, immunohistochemistry or phospho-specific dot blot (for phospho-specific antibodies only). The majority of our antibodies are validated in native lysates by western blot (fig A) and many are additionally qualified using transiently transfected lysates using an expression ready cDNA (fig B). Many of our antibodies qualified by western blot are also tested using immunohistochemistry (fig C). Our phospho-specific antibodies are qualified using phospho-specific dot blot analysis, which compares the antibody’s preferential binding to the phosphorylated peptide epitope (P) vs. non-phosphorylated peptide (NP). 

Abgent develops primary antibodies and provides first-in-class custom peptide synthesis & antibody development. Our antibodies are widely used for Autophagy, Apoptosis, Protein Partitioning, Phosphorylation, Cell Function & Disease & Gene Regulation research. Synthesis of difficult peptides is a core competency. High-quality, rapid turnaround & personal support is guaranteed.